- About
- PsychU For You
- Topics
- Events
- Content
Beyond Memory Loss: Optimizing The Role Of Primary Care In Assessing & Treating Agitation In Alzheimer’s Dementia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Beyond Memory Loss: Optimizing The Role Of Primary Care In Assessing & Treating Agitation In Alzheimer’s Dementia
Challenges in the treatment of agitation associated with Alzheimer’s Dementia (AAD) presents across multiple treatment settings. As the prevalence of Alzheimer’s Dementia continues to significantly increase, Primary Care will play an important role in not only assessing for cognitive declines in older adults but also in managing the diagnosis and treatment of AAD. This webinar will dive into the unmet needs within this patient population and feature experts in the management of AAD within the primary care setting. Specifically, presenters will review the prevalence of AAD, describe challenges in diagnosing AAD, and explore the potential pathobiological correlates in AAD. The webinar will discuss the clinical and humanistic burden of AAD, as well as highlight the current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease.
C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut
MoreBrendan Montano, MD, is the owner and medical director of Montano Wellness, LLC, and director of and a principal investigator for CT Clinical Research, all in Cromwell, Connecticut. Dr Montano is also an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut, a clinical instructor at Springfield College in Springfield, Massachusetts, and a primary care section advisor online for PsychU. He earned his medical degree from Albany College in Albany, New York. He completed his residency in internal medicine at Saint Francis Hospital and Medical Center in Hartford, Connecticut. Dr Montano has served as a principal investigator for over 120 clinical trials to evaluate the safety and efficacy of novel therapeutics for indications such as attention-deficit/hyperactivity disorder, major depressive disorder, and many other psychiatric and neurologic conditions. He is an editorial board member of The Primary Care Companion for CNS Disorders.
Elika Hefazi, PharmD, BCPP (OPDC)
Medical Science Liaison
Elizabeth DiNapoli, PhD (OPDC)
Senior Medical Science Liaison
MoreDr. DiNapoli earned her PhD from the University of Alabama.Speaker Dr. C. Brendan Montano is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speakers Elika Hefazi, PharmD, BCPP and Beth DiNapoli, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Registration
- PsychU For You
